American Association for Cancer Research
615 Chestnut St.
17th Floor
Philadelphia
Pennsylvania
19106-3483
United States
Tel: 215-440-9300
Fax: 215-440-9313
Website: http://www.aacr.org/
Email: webmaster@aacr.org
1394 articles with American Association for Cancer Research
-
The new facility is expected to bolster innovation across all facets of manufacturing to allow the company to fully develop and commercialize cancer treatments for patients in need.
-
The AACR annual meeting concluded on April 13, showcasing hundreds of preclinical to late-stage information from ongoing studies on treatment candidates.
-
The American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans. Here’s a look at some of the preclinical and early-stage studies recently presented.
-
The speakers extolled the benefits of telehealth while noting the challenges posed by a lack of high-speed Internet in some parts of the country.
-
Beatrice Mintz, the research legend passed away at the age of 100. Her contribution to the field is unforgettable. ere's more about her and the research.
-
Debbie's Dream Foundation Partners with American Association for Cancer Research to Announce $200,000 Research Grant for Stomach Cancer
9/17/2021
Debbie's Dream Foundation: Curing Stomach Cancer has partnered with the American Association for Cancer Research to encourage and inspire more research in the field of gastric cancer through a $200,000 research grant.
-
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
7/15/2021
Awards totaling more than $2 million aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies
-
Shares of iTeos Therapeutics skyrocketed more than 50% in premarket trading after it struck an agreement with GSM to co-develop and commercialize a cancer treatment.
-
Immunicom Presents Promising Clinical Trial Data at AACR in Late-Stage Breast Cancer Patients Treated with Novel Non-Pharmaceutical Immunotherapy
6/10/2021
Immunicom, Inc. presented preliminary data from its late-stage, metastatic triple-negative breast cancer (mTNBC) clinical trial at the American Association of Cancer Research (AACR) Annual Meeting 2021.
-
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
-
The FDA further delays Iovance’s filing for its TIL therapy as it requests additional data on the treatment’s potency assays.
-
The Series A rounds are the latest in a string of financing announcements made over the past few months.
-
2021 is shaping up to be another banner year for biotech companies as they advance the next gen technologies and therapeutics for the health of all. Here’s a few raking in cash for their programs today.
-
GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021
4/14/2021
GeneLeap Bio., a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an ePoster entitled 'Hydrogel encapsulated TLR9 agonists show sustained tumor growth inhibition and prolong survival of CT26 tumor-bearing mice' at the American Association for Cancer Research 2021 Annual Meeting.
-
ANGLE's Parsortix system showcased at AACR 2021
4/12/2021
Immunotherapy assay enables determination of PD-L1 status in significant proportion of patients and could guide personalised treatment selection
-
Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
4/11/2021
Eli Lilly and Company announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo® demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal malignancies.
-
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
4/11/2021
The combination showed preliminary antitumor activity in patients with unresectable or metastatic melanoma refractory or resistant to PD-1/L1 inhibitors and platinum-resistant ovarian cancer in an ongoing Phase 1b clinical trial, with a generally well-tolerated safety profile.
-
Zymeworks Showcases Preclinical Assets, Including New Therapeutic Platform, ProTECT™, and Zanidatamab Mechanisms of Action at AACR Annual Meeting
4/10/2021
Zanidatamab preclinical data reveals additional differentiated mechanisms of action including unique ability to induce complement dependent cytotoxicity
-
Tachyon Presents Promising Preclinical Data on Its First-in-class Pan-KDM4 Epigenetic Regulator, TACH101
4/10/2021
Tachyon Therapeutics, Inc., a research and development biotechnology company, announced a presentation of data of the Company’s novel compound, TACH101, at the American Association for Cancer Research Annual Meeting.
-
Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities
4/10/2021
Synthekine Inc., an engineered cytokine therapeutics company, announced preclinical data presented at the American Association of Cancer Research Annual Meeting 2021 demonstrating its alpha/beta selective IL-2 partial agonist, STK-012, induced potent anti-tumor activity while avoiding the toxicities that have hindered the development of IL-2 therapeutics, including vascular leak syndrome.